Tradestie Institutional Equity Comparison Engine
IG vs ICCC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ICCC Overall Edge
ICCC Captures Institutional Edge (3โ0 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, IG trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ICCC at N/M Forward P/E and 15.2% operating margin (+11.5% YoY). In options structure, IG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
ICCC
IG N/M vs ICCC N/M Fwd P/E
Growth & Margin Winner
ICCC
Op Margin N/A vs 15.2% ยท YoY N/A vs +11.5%
Momentum & Technical Winner
ICCC
1Y -6.1% vs +88.8% ยท 52W Pos 14% vs 91%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
IG
NYSE Arca
Principal Investment Grade Corporate Active ETF
Institutional Equity
$19.61
-0.02% 1D
Market Cap
N/A
1M Return
-0.61%
1Y Return
-6.14%
Forward P/E
N/M
Unified AI Score
45.4 / 100
HOLD
Tech 49.0
Fund 53.0
Flow 50.0
Mom 46.0
ICCC
NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap
$97.7M
1M Return
+6.23%
1Y Return
+88.76%
Forward P/E
N/M
Unified AI Score
43.8 / 100
HOLD
Tech 15.0
Fund 48.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
IG -6.14%
ICCC +88.76%
Spread: +94.9 pp (ICCC Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
IG TTM Op. Margin: N/A
ICCC TTM Op. Margin: 15.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IG vs ICCC. Trailing 12-month operating profitability (IG N/A vs ICCC 15.2%) and valuation multiples (IG N/M vs ICCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IG | ICCC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $97.7M | Larger Scale | ICCC |
| Trailing P/E Ratio Valuation | N/M | 56.6x | Lower Multiple | ICCC |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +11.5% | Higher Growth | ICCC |
| Operating Margin (TTM) Profitability | N/A | 15.2% | Higher Margin | ICCC |
| Net Profit Margin Profitability | N/A | 2.6% | Higher Margin | ICCC |
| Return on Equity (ROE) Capital Efficiency | N/A | 2.6% | Higher ROE | ICCC |
| 52-Week Range Position Momentum | 14% ($19โ$21) | 91% ($5โ$12) | Stronger Trend | ICCC |
| Beta / 30D Volatility Risk Regime | 0.18ฮฒ ยท 7% Vol | 0.24ฮฒ ยท 46% Vol | Lower Realized Risk | IG |
| Unified Institutional Score Composite Signal | 45.4 / 100 (HOLD) | 43.8 / 100 (HOLD) | Higher Composite | IG |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full IG vs ICCC Buy Guide
IG
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ICCC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither IG nor ICCC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.